Search

Your search keyword '"Laurence, Valérie"' showing total 220 results
Start Over Author "Laurence, Valérie"
220 results on '"Laurence, Valérie"'

1. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study

Author

Duffaud, Florence, Blay, Jean-Yves, Le Cesne, Axel, Chevreau, Christine, Boudou-Rouquette, Pascaline, Kalbacher, Elsa, Penel, Nicolas, Perrin, Christophe, Laurence, Valérie, Bompas, Emmanuelle, Saada-Bouzid, Esma, Delcambre, Corinne, Bertucci, François, Cancel, Mathilde, Schiffler, Camille, Monard, Laure, Bouvier, Corinne, Vidal, Vincent, Gaspar, Nathalie, and Chabaud, Sylvie

Published
2023
Full Text
View/download PDF

3. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

Author

Kubicek, Pierre, Cesne, Axel Le, Lervat, Cyril, Toulmonde, Maud, Chevreau, Christine, Duffaud, Florence, Le Nail, Louis-Romée, Morelle, Magali, Gaspar, Nathalie, Vérité, Cécile, Castex, Marie-Pierre, Penel, Nicolas, Saada, Esma, Causeret, Sylvain, Bertucci, François, Perrin, Christophe, Bompas, Emmanuelle, Orbach, Daniel, Laurence, Valérie, Piperno-Neumann, Sophie, Anract, Philippe, Rios, Maria, Gentet, Jean-Claude, Mascard, Éric, Pannier, Stéphanie, Blouin, Pascale, Carrère, Sébastien, Chaigneau, Loïc, Soibinet-Oudot, Pauline, Corradini, Nadège, Boudou-Rouquette, Pascaline, Ruzic, Jean-Christophe, Lebrun-Ly, Valérie, Dubray-Longeras, Pascale, Varatharajah, Sharmini, Lebbe, Céleste, Ropars, Mickaël, Kurtz, Jean-Emmanuel, Guillemet, Cécile, Lotz, Jean-Pierre, Berchoud, Juliane, Cherrier, Grégory, Ducimetière, Françoise, Chemin, Claire, Italiano, Antoine, Honoré, Charles, Desandes, Emmanuel, Blay, Jean-Yves, Gouin, François, and Marec-Bérard, Perrine

Published
2023
Full Text
View/download PDF

5. Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding

Author

Lee, Olivia W., Rodrigues, Calvin, Lin, Shu-Hong, Luo, Wen, Jones, Kristine, Brown, Derek W., Zhou, Weiyin, Karlins, Eric, Khan, Sairah M., Baulande, Sylvain, Raynal, Virginie, Surdez, Didier, Reynaud, Stephanie, Rubio, Rebeca Alba, Zaidi, Sakina, Grossetête, Sandrine, Ballet, Stelly, Lapouble, Eve, Laurence, Valérie, Pierron, Gaelle, Gaspar, Nathalie, Corradini, Nadège, Marec-Bérard, Perrine, Rothman, Nathaniel, Dagnall, Casey L., Burdett, Laurie, Manning, Michelle, Wyatt, Kathleen, Yeager, Meredith, Chari, Raj, Leisenring, Wendy M., Kulozik, Andreas E., Kriebel, Jennifer, Meitinger, Thomas, Strauch, Konstantin, Kirchner, Thomas, Dirksen, Uta, Mirabello, Lisa, Tucker, Margaret A., Tirode, Franck, Armstrong, Gregory T., Bhatia, Smita, Robison, Leslie L., Yasui, Yutaka, Romero-Pérez, Laura, Hartmann, Wolfgang, Metzler, Markus, Diver, W. Ryan, Lori, Adriana, Freedman, Neal D., Hoover, Robert N., Morton, Lindsay M., Chanock, Stephen J., Grünewald, Thomas G.P., Delattre, Olivier, and Machiela, Mitchell J.

Published
2023
Full Text
View/download PDF

6. Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age

Author

Bouttefroy, Séverine, Penel, Nicolas, Orbach, Daniel, Minard-Colin, Véronique, Le Cesne, Axel, Blay, Jean-Yves, Marec-Berard, Perrine, Verité, Cécile, Laurence, Valérie, Piperno-Neumann, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Chevreau, Christine, Duffaud, Florence, Salas, Sébastien, Morelle, Magali, Jean-Denis, Myriam, Italiano, Antoine, Bonvalot, Sylvie, and Corradini, Nadège

Published
2023
Full Text
View/download PDF

8. Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS

Author

Chvetzoff, Gisèle, Bouleuc, Carole, Lardy-Cléaud, Audrey, Saltel, Pierre, Dieras, Véronique, Morelle, Magali, Guastalla, Jean-Paul, Tredan, Olivier, Rebattu, Paul, Pop, Simona, Ray-Coquard, Isabelle, Pierga, Jean-Yves, Mignot, Laurent, Laurence, Valérie, Bourne-Branchu, Valérie, Pérol, David, and Bachelot, Thomas

Published
2023
Full Text
View/download PDF

10. Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network

Author

Bompas, Emmanuelle, Martin, Valentine, Meniai, Fatima, Toulmonde, Maud, Marec-Berard, Perrine, Claude, Line, Ducimetiere, Françoise, Chargari, Cyrus, Minard-Colin, Véronique, Corradini, Nadège, Laurence, Valérie, Piperno-Neumann, Sophie, Defachelles, Anne-Sophie, Bernier, Valérie, Italiano, Antoine, Orbach, Daniel, Blay, Jean-Yves, Gaspar, Nathalie, and Berlanga, Pablo

Published
2021
Full Text
View/download PDF

12. Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience.

Author

Bastard, Paul, Cozic, Nathalie, Brion, Régis, Gaspar, Nathalie, Piperno‐Neumann, Sophie, Cordero, Camille, Leculée‐Thébaud, Estelle, Gomez‐Mascard, Anne, Rédini, Françoise, Marchais, Antonin, Ikonomova, Raina, Cleirec, Morgane, Laurence, Valérie, Rigaud, Charlotte, Abbas, Rachid, Verrecchia, Franck, Brugières, Laurence, and Minard‐Colin, Véronique

Published
2024
Full Text
View/download PDF

14. First report of medulloblastoma in a patient with MUTYH‐associated polyposis

Author

Villy, Marie‐Charlotte, primary, Warcoin, Mathilde, additional, Filser, Mathilde, additional, Buecher, Bruno, additional, Golmard, Lisa, additional, Suybeng, Voreak, additional, Schwartz, Mathias, additional, Bieche, Ivan, additional, Vacher, Sophie, additional, Laurence, Valérie, additional, Bourdeaut, Franck, additional, Bernier, Michèle, additional, Gutman, Tom, additional, Stoppa‐Lyonnet, Dominique, additional, Masliah‐Planchon, Julien, additional, and Colas, Chrystelle, additional

Published
2023
Full Text
View/download PDF

15. The Place of Sick Peers in Adolescents and Young Adults with Cancer: Advantage, Disadvantage, and What Makes Barriers to the Encounter.

Author

Phan, Jeff, Laurence, Valérie, Marec-Berard, Perrine, Cordero, Camille, Riberon, Christèle, and Flahault, Cécile

Subjects
*CANCER patient psychology, *SOCIAL support, *RESEARCH methodology, *PEER counseling, *INTERVIEWING, *TUMORS in children, *PATIENTS' attitudes, *EXPERIENCE, *COMPARATIVE studies, *SUPPORT groups, *DESCRIPTIVE statistics, *RESEARCH funding, *TUMORS, *THEMATIC analysis, *FATIGUE (Physiology), *CANCER patient medical care, *LONGITUDINAL method, *COVID-19 pandemic, *ADULTS
Abstract

Purpose: The appreciation of peer support can vary from one country to another due to the cultural and relational differences. This study explores what perceptions French adolescents and young adults (AYAs) in post-treatment for cancer have of the place of sick peers during their treatment and what can make barriers to meet them. Methods: A semistructured interview has been proposed 6 months after the end of cancer treatments. A thematic analysis has been conducted to highlight the major themes and subthemes identified through the participants' discourses. Results: Twelve AYAs (mean age 23 y.o., standard deviation = 2.8; min = 19; max = 26) from two French cancer centers were interviewed. Five major themes were identified, but only two were presented in this article: the place of peers and the impact of coronavirus disease 2019 (COVID-19) epidemic on AYA facilities. AYA peers with cancer major theme demonstrated that meeting sick peers has benefits (e.g., identification, understanding, support, feeling of normalcy) but also has disadvantages (e.g., negative emotional influence). The benefits of peer-to-peer meetings seem to outweigh the disadvantages. Nevertheless, AYAs can face social barriers to this kind of relationship (e.g., fatigue, need to focus on oneself, confrontation to cancer and negative events, feeling of unnatural meeting). Finally, patients' encounters and the normal functioning of AYA facilities have been hampered by the COVID-19 pandemic. Conclusion: Even if AYA services systematically suggest a meeting with other sick peers, it is important to reiterate this proposal since the needs can evolve over time. It can also be interesting to propose places of life outside the hospital to make the encounters more comfortable and natural for AYAs. Clinical Trial Registration number: NCT03964116. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Supplementary Table 1 from Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Author

Tirode, Franck, primary, Surdez, Didier, primary, Ma, Xiaotu, primary, Parker, Matthew, primary, Le Deley, Marie Cécile, primary, Bahrami, Armita, primary, Zhang, Zhaojie, primary, Lapouble, Eve, primary, Grossetête-Lalami, Sandrine, primary, Rusch, Michael, primary, Reynaud, Stéphanie, primary, Rio-Frio, Thomas, primary, Hedlund, Erin, primary, Wu, Gang, primary, Chen, Xiang, primary, Pierron, Gaelle, primary, Oberlin, Odile, primary, Zaidi, Sakina, primary, Lemmon, Gordon, primary, Gupta, Pankaj, primary, Vadodaria, Bhavin, primary, Easton, John, primary, Gut, Marta, primary, Ding, Li, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Shurtleff, Sheila, primary, Laurence, Valérie, primary, Michon, Jean, primary, Marec-Bérard, Perrine, primary, Gut, Ivo, primary, Downing, James, primary, Dyer, Michael, primary, Zhang, Jinghui, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 4 from Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Author

Tirode, Franck, primary, Surdez, Didier, primary, Ma, Xiaotu, primary, Parker, Matthew, primary, Le Deley, Marie Cécile, primary, Bahrami, Armita, primary, Zhang, Zhaojie, primary, Lapouble, Eve, primary, Grossetête-Lalami, Sandrine, primary, Rusch, Michael, primary, Reynaud, Stéphanie, primary, Rio-Frio, Thomas, primary, Hedlund, Erin, primary, Wu, Gang, primary, Chen, Xiang, primary, Pierron, Gaelle, primary, Oberlin, Odile, primary, Zaidi, Sakina, primary, Lemmon, Gordon, primary, Gupta, Pankaj, primary, Vadodaria, Bhavin, primary, Easton, John, primary, Gut, Marta, primary, Ding, Li, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Shurtleff, Sheila, primary, Laurence, Valérie, primary, Michon, Jean, primary, Marec-Bérard, Perrine, primary, Gut, Ivo, primary, Downing, James, primary, Dyer, Michael, primary, Zhang, Jinghui, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 2 from Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Author

Tirode, Franck, primary, Surdez, Didier, primary, Ma, Xiaotu, primary, Parker, Matthew, primary, Le Deley, Marie Cécile, primary, Bahrami, Armita, primary, Zhang, Zhaojie, primary, Lapouble, Eve, primary, Grossetête-Lalami, Sandrine, primary, Rusch, Michael, primary, Reynaud, Stéphanie, primary, Rio-Frio, Thomas, primary, Hedlund, Erin, primary, Wu, Gang, primary, Chen, Xiang, primary, Pierron, Gaelle, primary, Oberlin, Odile, primary, Zaidi, Sakina, primary, Lemmon, Gordon, primary, Gupta, Pankaj, primary, Vadodaria, Bhavin, primary, Easton, John, primary, Gut, Marta, primary, Ding, Li, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Shurtleff, Sheila, primary, Laurence, Valérie, primary, Michon, Jean, primary, Marec-Bérard, Perrine, primary, Gut, Ivo, primary, Downing, James, primary, Dyer, Michael, primary, Zhang, Jinghui, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

19. Data from Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Author

Tirode, Franck, primary, Surdez, Didier, primary, Ma, Xiaotu, primary, Parker, Matthew, primary, Le Deley, Marie Cécile, primary, Bahrami, Armita, primary, Zhang, Zhaojie, primary, Lapouble, Eve, primary, Grossetête-Lalami, Sandrine, primary, Rusch, Michael, primary, Reynaud, Stéphanie, primary, Rio-Frio, Thomas, primary, Hedlund, Erin, primary, Wu, Gang, primary, Chen, Xiang, primary, Pierron, Gaelle, primary, Oberlin, Odile, primary, Zaidi, Sakina, primary, Lemmon, Gordon, primary, Gupta, Pankaj, primary, Vadodaria, Bhavin, primary, Easton, John, primary, Gut, Marta, primary, Ding, Li, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Shurtleff, Sheila, primary, Laurence, Valérie, primary, Michon, Jean, primary, Marec-Bérard, Perrine, primary, Gut, Ivo, primary, Downing, James, primary, Dyer, Michael, primary, Zhang, Jinghui, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table and Figure Legends from Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Author

Tirode, Franck, primary, Surdez, Didier, primary, Ma, Xiaotu, primary, Parker, Matthew, primary, Le Deley, Marie Cécile, primary, Bahrami, Armita, primary, Zhang, Zhaojie, primary, Lapouble, Eve, primary, Grossetête-Lalami, Sandrine, primary, Rusch, Michael, primary, Reynaud, Stéphanie, primary, Rio-Frio, Thomas, primary, Hedlund, Erin, primary, Wu, Gang, primary, Chen, Xiang, primary, Pierron, Gaelle, primary, Oberlin, Odile, primary, Zaidi, Sakina, primary, Lemmon, Gordon, primary, Gupta, Pankaj, primary, Vadodaria, Bhavin, primary, Easton, John, primary, Gut, Marta, primary, Ding, Li, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Shurtleff, Sheila, primary, Laurence, Valérie, primary, Michon, Jean, primary, Marec-Bérard, Perrine, primary, Gut, Ivo, primary, Downing, James, primary, Dyer, Michael, primary, Zhang, Jinghui, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 3 from Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Author

Tirode, Franck, primary, Surdez, Didier, primary, Ma, Xiaotu, primary, Parker, Matthew, primary, Le Deley, Marie Cécile, primary, Bahrami, Armita, primary, Zhang, Zhaojie, primary, Lapouble, Eve, primary, Grossetête-Lalami, Sandrine, primary, Rusch, Michael, primary, Reynaud, Stéphanie, primary, Rio-Frio, Thomas, primary, Hedlund, Erin, primary, Wu, Gang, primary, Chen, Xiang, primary, Pierron, Gaelle, primary, Oberlin, Odile, primary, Zaidi, Sakina, primary, Lemmon, Gordon, primary, Gupta, Pankaj, primary, Vadodaria, Bhavin, primary, Easton, John, primary, Gut, Marta, primary, Ding, Li, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Shurtleff, Sheila, primary, Laurence, Valérie, primary, Michon, Jean, primary, Marec-Bérard, Perrine, primary, Gut, Ivo, primary, Downing, James, primary, Dyer, Michael, primary, Zhang, Jinghui, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 5 from Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Author

Tirode, Franck, primary, Surdez, Didier, primary, Ma, Xiaotu, primary, Parker, Matthew, primary, Le Deley, Marie Cécile, primary, Bahrami, Armita, primary, Zhang, Zhaojie, primary, Lapouble, Eve, primary, Grossetête-Lalami, Sandrine, primary, Rusch, Michael, primary, Reynaud, Stéphanie, primary, Rio-Frio, Thomas, primary, Hedlund, Erin, primary, Wu, Gang, primary, Chen, Xiang, primary, Pierron, Gaelle, primary, Oberlin, Odile, primary, Zaidi, Sakina, primary, Lemmon, Gordon, primary, Gupta, Pankaj, primary, Vadodaria, Bhavin, primary, Easton, John, primary, Gut, Marta, primary, Ding, Li, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Shurtleff, Sheila, primary, Laurence, Valérie, primary, Michon, Jean, primary, Marec-Bérard, Perrine, primary, Gut, Ivo, primary, Downing, James, primary, Dyer, Michael, primary, Zhang, Jinghui, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figures 1 - 5 from Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Author

Tirode, Franck, primary, Surdez, Didier, primary, Ma, Xiaotu, primary, Parker, Matthew, primary, Le Deley, Marie Cécile, primary, Bahrami, Armita, primary, Zhang, Zhaojie, primary, Lapouble, Eve, primary, Grossetête-Lalami, Sandrine, primary, Rusch, Michael, primary, Reynaud, Stéphanie, primary, Rio-Frio, Thomas, primary, Hedlund, Erin, primary, Wu, Gang, primary, Chen, Xiang, primary, Pierron, Gaelle, primary, Oberlin, Odile, primary, Zaidi, Sakina, primary, Lemmon, Gordon, primary, Gupta, Pankaj, primary, Vadodaria, Bhavin, primary, Easton, John, primary, Gut, Marta, primary, Ding, Li, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Shurtleff, Sheila, primary, Laurence, Valérie, primary, Michon, Jean, primary, Marec-Bérard, Perrine, primary, Gut, Ivo, primary, Downing, James, primary, Dyer, Michael, primary, Zhang, Jinghui, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

24. Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding

Author

Lee, Olivia W, Rodrigues, Calvin, Lin, Shu-Hong, Luo, Wen, Jones, Kristine, Brown, Derek W, Zhou, Weiyin, Karlins, Eric, Khan, Sairah M, Baulande, Sylvain, Raynal, Virginie, Surdez, Didier; https://orcid.org/0000-0002-7118-7859, Reynaud, Stephanie, Rubio, Rebeca Alba, Zaidi, Sakina, Grossetête, Sandrine, Ballet, Stelly, Lapouble, Eve, Laurence, Valérie, Pierron, Gaelle, Gaspar, Nathalie, Corradini, Nadège, Marec-Bérard, Perrine, Rothman, Nathaniel, Dagnall, Casey L, Burdett, Laurie, Manning, Michelle, Wyatt, Kathleen, Yeager, Meredith, Chari, Raj, et al, Lee, Olivia W, Rodrigues, Calvin, Lin, Shu-Hong, Luo, Wen, Jones, Kristine, Brown, Derek W, Zhou, Weiyin, Karlins, Eric, Khan, Sairah M, Baulande, Sylvain, Raynal, Virginie, Surdez, Didier; https://orcid.org/0000-0002-7118-7859, Reynaud, Stephanie, Rubio, Rebeca Alba, Zaidi, Sakina, Grossetête, Sandrine, Ballet, Stelly, Lapouble, Eve, Laurence, Valérie, Pierron, Gaelle, Gaspar, Nathalie, Corradini, Nadège, Marec-Bérard, Perrine, Rothman, Nathaniel, Dagnall, Casey L, Burdett, Laurie, Manning, Michelle, Wyatt, Kathleen, Yeager, Meredith, Chari, Raj, and et al

Abstract

Ewing sarcoma (EwS) is a rare bone and soft tissue malignancy driven by chromosomal translocations encoding chimeric transcription factors, such as EWSR1-FLI1, that bind GGAA motifs forming novel enhancers that alter nearby expression. We propose that germline microsatellite variation at the 6p25.1 EwS susceptibility locus could impact downstream gene expression and EwS biology. We performed targeted long-read sequencing of EwS blood DNA to characterize variation and genomic features important for EWSR1-FLI1 binding. We identified 50 microsatellite alleles at 6p25.1 and observed that EwS-affected individuals had longer alleles (>135 bp) with more GGAA repeats. The 6p25.1 GGAA microsatellite showed chromatin features of an EWSR1-FLI1 enhancer and regulated expression of RREB1, a transcription factor associated with RAS/MAPK signaling. RREB1 knockdown reduced proliferation and clonogenic potential and reduced expression of cell cycle and DNA replication genes. Our integrative analysis at 6p25.1 details increased binding of longer GGAA microsatellite alleles with acquired EWSR-FLI1 to promote Ewing sarcomagenesis by RREB1-mediated proliferation.

Published
2023

25. Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS

Author

Chvetzoff, Gisèle, primary, Bouleuc, Carole, additional, Lardy-Cléaud, Audrey, additional, Saltel, Pierre, additional, Dieras, Véronique, additional, Morelle, Magali, additional, Guastalla, Jean-Paul, additional, Tredan, Olivier, additional, Rebattu, Paul, additional, Pop, Simona, additional, Ray-Coquard, Isabelle, additional, Pierga, Jean-Yves, additional, Mignot, Laurent, additional, Laurence, Valérie, additional, Bourne-Branchu, Valérie, additional, Pérol, David, additional, and Bachelot, Thomas, additional

Published
2022
Full Text
View/download PDF

26. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma

Author

Sheffield, Nathan C, Pierron, Gaelle, Klughammer, Johanna, Datlinger, Paul, Schönegger, Andreas, Schuster, Michael, Hadler, Johanna, Surdez, Didier, Guillemot, Delphine, Lapouble, Eve, Freneaux, Paul, Champigneulle, Jacqueline, Bouvier, Raymonde, Walder, Diana, Ambros, Ingeborg M, Hutter, Caroline, Sorz, Eva, Amaral, Ana T, de Álava, Enrique, Schallmoser, Katharina, Strunk, Dirk, Rinner, Beate, Liegl-Atzwanger, Bernadette, Huppertz, Berthold, Leithner, Andreas, de Pinieux, Gonzague, Terrier, Philippe, Laurence, Valérie, Michon, Jean, Ladenstein, Ruth, Holter, Wolfgang, Windhager, Reinhard, Dirksen, Uta, Ambros, Peter F, Delattre, Olivier, Kovar, Heinrich, Bock, Christoph, and Tomazou, Eleni M

Subjects
Methylation -- Health aspects, Cancer cells -- Genetic aspects, Ewing's sarcoma -- Genetic aspects, Biological sciences, Health
Abstract

Developmental tumors in children and young adults carry few genetic alterations, yet they have diverse clinical presentation. Focusing on Ewing sarcoma, we sought to establish the prevalence and characteristics of epigenetic heterogeneity in genetically homogeneous cancers. We performed genome-scale DNA methylation sequencing for a large cohort of Ewing sarcoma tumors and analyzed epigenetic heterogeneity on three levels: between cancers, between tumors, and within tumors. We observed consistent DNA hypomethylation at enhancers regulated by the disease-defining EWS-FLI1 fusion protein, thus establishing epigenomic enhancer reprogramming as a ubiquitous and characteristic feature of Ewing sarcoma. DNA methylation differences between tumors identified a continuous disease spectrum underlying Ewing sarcoma, which reflected the strength of an EWS-FLI1 regulatory signature and a continuum between mesenchymal and stem cell signatures. There was substantial epigenetic heterogeneity within tumors, particularly in patients with metastatic disease. In summary, our study provides a comprehensive assessment of epigenetic heterogeneity in Ewing sarcoma and thereby highlights the importance of considering nongenetic aspects of tumor heterogeneity in the context of cancer biology and personalized medicine., Author(s): Nathan C Sheffield [1]; Gaelle Pierron [2]; Johanna Klughammer [1]; Paul Datlinger [1]; Andreas Schönegger [1]; Michael Schuster [1]; Johanna Hadler [1]; Didier Surdez [3]; Delphine Guillemot [2]; Eve [...]

Published
2017
Full Text
View/download PDF

28. Late toxicity comparison of alkylating‐based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro‐EWING99‐R1 in France

Author

Corvest, Victoria, primary, Marec‐Bérard, Perrine, additional, Lervat, Cyril, additional, Pacquement, Hélène, additional, Toulmonde, Maud, additional, Gentet, Jean‐Claude, additional, Laurence, Valérie, additional, Cleirec, Morgane, additional, Mansuy, Ludovic, additional, Bompas, Emmanuelle, additional, Castex, Marie‐Pierre, additional, Taque, Sophie, additional, Filhon, Bruno, additional, Tabone, Marie‐Dominique, additional, Verité, Cécile, additional, Entz‐Werle, Natacha, additional, Saumet, Laure, additional, Guimard, Gregory, additional, Pondrom, Morgane, additional, Chevreau, Christine, additional, Flandrin, Jennifer, additional, Duranteau, Lise, additional, Rousset‐Jablonski, Christine, additional, Brugières, Laurence, additional, Jimenez, Marta, additional, Le Deley, Marie‐Cécile, additional, Gaspar, Nathalie, additional, and Fresneau, Brice, additional

Published
2022
Full Text
View/download PDF

31. Psychological Adjustment, Adaptation, and Perception of Social Support in French Adolescents and Young Adults After the Diagnosis of Cancer.

Author

Phan, Jeff, Vander Haegen, Marie, Karsenti, Lucille, Laurence, Valérie, Marec-Berard, Perrine, Cordero, Camille, Thisse, Audrey, Riberon, Christèle, and Flahault, Cécile

Subjects
STATISTICS, KRUSKAL-Wallis Test, CANCER patient psychology, SOCIAL support, WIT & humor, DISTRACTION, PATIENT satisfaction, TUMORS in children, QUESTIONNAIRES, DESCRIPTIVE statistics, MENTAL depression, RESEARCH funding, TUMORS, PSYCHOLOGICAL adaptation, DATA analysis, ANXIETY
Abstract

Purpose: The third Cancer Plan (2014–2019) has helped with the recognition of adolescents and young adults (AYAs) with cancer's medical and psychosocial specificities and has enabled the creation of dedicated structures in France. Methods: The study involved 43 AYA patients (Nmen = 21; Nwomen = 22) between 15 and 27 years old (Mage = 19.9), diagnosed with all types of cancer, and were recruited in two French cancer centers. Online questionnaires were filled in 2 months after the beginning of treatment. AYAs completed measures of depressive and anxiety symptoms, perceived social support, and coping strategies. Results: Results demonstrated moderate depressive symptoms (M = 10.7, standard deviation [SD] = 7.0) and suggested a good satisfaction (M = 30, SD = 9.5) and a mild availability (M = 27, SD = 10.3) of the social support. Spearman's correlations demonstrated that coping strategies are related to depressive symptoms, for which acceptance (p < 0.01) of the disease played a key role in their psychological adjustment. Perceived social support subscales were positively correlated with the use of distraction as a coping strategy (p < 0.05). Kruskal–Wallis test demonstrated the preferential use of instrumental (p < 0.05) and emotional support (p < 0.01), denial (p < 0.01), and self-blame (p < 0.01) for women and the use of acceptance (p < 0.05) and humor (p < 0.05) for men; and there were no significant differences between patients hospitalized in the two cancer center facilities. Conclusion: Finally, a better understanding of the psychological adjustment and processes among French AYAs with cancer will help families and processionals to better adjust AYA-specific needs at the beginning of cancer treatment. ClinicalTrials.gov.: NCT03964116. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility

Author

Machiela, Mitchell J., Grünewald, Thomas G. P., Surdez, Didier, Reynaud, Stephanie, Mirabeau, Olivier, Karlins, Eric, Rubio, Rebeca Alba, Zaidi, Sakina, Grossetete-Lalami, Sandrine, Ballet, Stelly, Lapouble, Eve, Laurence, Valérie, Michon, Jean, Pierron, Gaelle, Kovar, Heinrich, Gaspar, Nathalie, Kontny, Udo, González-Neira, Anna, Picci, Piero, Alonso, Javier, Patino-Garcia, Ana, Corradini, Nadège, Bérard, Perrine Marec, Freedman, Neal D., Rothman, Nathaniel, Dagnall, Casey L., Burdett, Laurie, Jones, Kristine, Manning, Michelle, Wyatt, Kathleen, Zhou, Weiyin, Yeager, Meredith, Cox, David G., Hoover, Robert N., Khan, Javed, Armstrong, Gregory T., Leisenring, Wendy M., Bhatia, Smita, Robison, Leslie L., Kulozik, Andreas E., Kriebel, Jennifer, Meitinger, Thomas, Metzler, Markus, Hartmann, Wolfgang, Strauch, Konstantin, Kirchner, Thomas, Dirksen, Uta, Morton, Lindsay M., Mirabello, Lisa, Tucker, Margaret A., Tirode, Franck, Chanock, Stephen J., and Delattre, Olivier

Published
2018
Full Text
View/download PDF

33. Management and Outcomes of Pediatric, Adolescent and Young Adult Sarcoma Patients: Results from the French Nationwide Database NETSARC

Author

Kubicek, Pierre, primary, Cesne, Axel Le, additional, Lervat, Cyril, additional, Toulmonde, Maud, additional, Chevreau, Christine, additional, Duffaud, Florence, additional, Nail, Louis-Romée Le, additional, Morelle, Magali, additional, Gaspar, Nathalie, additional, Vérité, Cécile, additional, Castex, Marie-Pierre, additional, Penel, Nicolas, additional, Saada, Esma, additional, Causeret, Sylvain, additional, Bertucci, François, additional, Perrin, Christophe, additional, Bompas, Emmanuelle, additional, Orbach, Daniel, additional, Laurence, Valérie, additional, Piperno-Neumann, Sophie, additional, Anract, Philippe, additional, Rios, Maria, additional, Gentet, Jean-Claude, additional, Mascard, Éric, additional, Pannier, Stéphanie, additional, Blouin, Pascale, additional, Carrère, Sébastien, additional, Chaigneau, Loïc, additional, Soibinet-Oudot, Pauline, additional, Corradini, Nadège, additional, Boudou-Rouquette, Pascaline, additional, Ruzic, Jean-Christophe, additional, Lebrun-Ly, Valérie, additional, Dubray-Longeras, Pascale, additional, Varatharajah, Sharmini, additional, Lebbe, Céleste, additional, Ropars, Mickaël, additional, Kurtz, Jean-Emmanuel, additional, Guillemet, Cécile, additional, Lotz, Jean-Pierre, additional, Berchoud, Juliane, additional, Cherrier, Grégory, additional, Ducimetière, Françoise, additional, Chemin, Claire, additional, Italiano, Antoine, additional, Honoré, Charles, additional, Desandes, Emmanuel, additional, Blay, Jean-Yves, additional, Gouin, François, additional, and Marec-Bérard, Perrine, additional

Published
2022
Full Text
View/download PDF

34. Late toxicity comparison of alkylating‐based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro‐EWING99‐R1 in France.

Author

Corvest, Victoria, Marec‐Bérard, Perrine, Lervat, Cyril, Pacquement, Hélène, Toulmonde, Maud, Gentet, Jean‐Claude, Laurence, Valérie, Cleirec, Morgane, Mansuy, Ludovic, Bompas, Emmanuelle, Castex, Marie‐Pierre, Taque, Sophie, Filhon, Bruno, Tabone, Marie‐Dominique, Verité, Cécile, Entz‐Werle, Natacha, Saumet, Laure, Guimard, Gregory, Pondrom, Morgane, and Chevreau, Christine

Subjects
EWING'S sarcoma, IFOSFAMIDE, CLINICAL trials, NEPHROTOXICOLOGY, CYCLOPHOSPHAMIDE
Abstract

In Euro‐EWING99‐R1 randomized trial, cyclophosphamide was shown to be noninferior to ifosfamide in the consolidation of standard‐risk Ewing sarcoma (SR‐EWS) after a common induction with VIDE (vincristine‐ifosfamide‐doxorubicin‐etoposide). We present the results of the late effects analysis of VAC (vincristine‐dactinomycin‐cyclophoshamide) vs VAI (vincristine‐dactinomycin‐ifosfamide) conducted in Euro‐EWING99‐R1 French cohort. Of 267 French randomized patients, 204 were alive and free‐of‐relapse at 5‐years including 172 with available long‐term follow‐up data concerning cardiac, renal and/or gonadal functions (sex‐ratio M/F = 1.3, median age at diagnosis = 14 years): 84 randomized in VAC (median cumulative doses: cyclophosphamide = 9.7 g/m2, ifosfamide = 59.4 g/m2) and 88 in VAI (ifosfamide = 97.1 g/m2). With a median follow‐up of 10 years (range = 5‐17), five late relapses and five second malignancies were recorded. The 10‐year event‐free survival among 5‐year free‐of‐relapse survivors was similar between VAC and VAI (93% vs 95%, P =.63). We estimated the 10‐year cumulative probabilities of cardiac and kidney toxicities at 4.4% (95% confidence interval [95% CI] = 1.1%‐7.6%) and 34.8% (95% CI = 26.8%‐42.0%), respectively. Cardiac toxicity cumulative probability was similar in both arms, whereas kidney toxicity was higher in VAI (at 10 years, 43.0% vs 25.7%, P =.02), resulting from significant difference in glomerular toxicity (31.1% vs 13.1%, P <.01). At 10 years, gonadal toxicity was observed in 27% and 28% of pubertal men and women, respectively, without significant difference between VAC and VAI. Kidney and gonadal toxicities represent major issues in Euro‐EWING99‐R1, with significantly higher risk of kidney toxicities with VAI, without significant gonadal toxicity reduction. These results support the need to limit cumulative doses of both alkylating agents and to use mixed regimen as in VIDE‐VAC or VDC/IE (vincristine‐doxorubicin‐cyclophoshamide/ifosfamide‐etoposide). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Theatre of the Oppressed in French as a second language

Author

Laurence Valérie Thibault

Subjects
050101 languages & linguistics, Linguistics and Language, Teamwork, Communication, Teaching method, media_common.quotation_subject, 05 social sciences, 050301 education, Intercultural communication, Linguistics, Nonverbal communication, Second language, Power structure, 0501 psychology and cognitive sciences, Reflection (computer graphics), Psychology, 0503 education, Cultural competence, media_common
Abstract

This article presents a personal reflection on the potential for the techniques of the Theatre of the Oppressed (TO) to help French as a Second Language (FSL) university students develop communicat...

Published
2020

38. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

Author

European Commission, Société Française de chirurgie Endoscopique, Ligue Nationale contre le Cancer (France), University of Birmingham, Cancer Research UK, Anderton, Jennifer, Moroz, Verónica, Marec-Bérard, Perrine, Gaspar, Nathalie, Laurence, Valérie, Martín-Broto, Javier, Sastre, Ana, Gelderblom, Hans, Owens, Cormac, Kaiser, Sophie, Fernández-Pinto, Melissa, Fenwick, Nicola, Evans, Abigail, Strauss, Sandra, Whelan, Jeremy, Wheatley, Keith, Brennan, Bernadette, European Commission, Société Française de chirurgie Endoscopique, Ligue Nationale contre le Cancer (France), University of Birmingham, Cancer Research UK, Anderton, Jennifer, Moroz, Verónica, Marec-Bérard, Perrine, Gaspar, Nathalie, Laurence, Valérie, Martín-Broto, Javier, Sastre, Ana, Gelderblom, Hans, Owens, Cormac, Kaiser, Sophie, Fernández-Pinto, Melissa, Fenwick, Nicola, Evans, Abigail, Strauss, Sandra, Whelan, Jeremy, Wheatley, Keith, and Brennan, Bernadette

Abstract

[Background] Although there have been multiple randomised trials in newly diagnosed Ewing sarcoma family of tumours (ESFT) and these have been conducted over many years and involved many international cooperative groups, the outcomes for all stages of disease have plateaued. Internationally, the standard treatment of ESFT is not defined, and there is a need to add new agents other than conventional chemotherapy to improve outcomes. This trial will compare two different induction/consolidation chemotherapy regimens: (1) vincristine, ifosfamide, doxorubicin and etoposide (VIDE) induction and vincristine, actinomycin D, ifosfamide or cyclophosphamide, or busulfan and mephalan (VAI/VAC/BuMel) consolidation and (2) vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide (VDC/IE) induction and ifosfamide and etoposide, vincristine and cyclophosphamide, vincristine, actinomycin D and ifosfamide, or busulfan and mephalan (IE/VC/VAI/BuMel) consolidation (randomisation 1, or R1). A second randomisation (R2) will determine whether the addition of zoledronic acid to consolidation chemotherapy, as assigned at R1, is associated with improved clinical outcome., [Methods] EURO EWING 2012 is an international, multicentre, phase III, open-label randomised controlled trial. There are two randomisations: R1 and R2. Patients are randomly assigned at two different time points: at entry to the trial (R1) and following local control therapy (R2). The primary outcome measure is event-free survival. The secondary outcome measures include overall survival, adverse events and toxicity, histological response of the primary tumour, response of the primary tumour, regional lymph nodes or metastases (or both), and achievement of local control at the end of treatment., [Discussion] This study will establish which is the “standard regimen” of chemotherapy, taking into account both clinical outcomes and toxicity. This will form the chemotherapy backbone for future interventional studies where we may want to add new targeted agents. It will also determine the role of zoledronic acid in conjunction with the separate EE2008 trial. Any trial in ESFT needs to take into account the rarity of the tumour and consider that international cooperation is needed to provide answers in a timely manner., [Trial registration] Registered with EudraCT number 2012-002107-17 on 26 February 2012. Registered with ISRCTN number 92192408 on 4 November 2013.

Published
2020

39. Défis et évolution de l'accompagnement offert aux professeurs de langue par le Régime d'immersion en français (RIF) de l'Université d'Ottawa

Author

Laurence Valérie Thibault and Marc Gobeil

Abstract

Depuis 2006, le RIF offre des cours d’encadrement linguistique (CEL) associés à des cours de discipline enseignés dans cinq facultés de l’université (soit 86 programmes en 2016-2017). Cependant, les professeurs de FLS sont très rarement formés à l’enseignement propre à ce type de cours qui sont développés sur mesure en lien avec chaque cours de discipline. Pour répondre à ce défi, le RIF offre, par l’entremise des responsables pédagogiques, un accompagnement dont la nature et le format ont évolué au fil des ans.D’abord, les professeurs ont reçu une formation initiale (création de ressources, réunions, ateliers, observations de classes suivies de recommandation) (Weinberg, A., et S. Burger, 2006). Puis, les responsables pédagogiques ont créé deux recueils rassemblant des activités conçues par les professeurs désormais expérimentés (Dansereau et Buchanan, 2009, 2011; Dansereau, 2011). Ces recueils sont devenus des incontournables pour les nouvelles recrues et ont contribué au développement d'une communauté de pratique. Aujourd'hui, l'accompagnement se caractérise par des consultations, des rencontres de partage de pratique et la vérification du respect des objectifs pédagogiques dans les plans de cours.Dans quelle mesure l’accompagnement reçu jusqu’à présent répond-il aux besoins des professeurs? Quels sont leurs nouveaux besoins ? Dans quelle direction et sous quelle forme l’accompagnement peut-il évoluer de façon à maximiser et reconnaître les savoir-faire développés par cette communauté de pratique afin qu’elle profite au plus grand nombre? Grâce aux résultats d’un sondage envoyé en janvier 2017 à tous les professeurs ayant enseigné un CEL depuis 2006 nous pouvons identifier les forces et les faiblesses de l’accompagnement déjà offert et envisager la mise en place de nouvelles stratégies d’accompagnement.

Published
2018

40. Coping Strategies and Factors Related to Problematic Substance Use and Behavioral Addictions Among Adolescents and Young Adults with Cancer

Author

Grégoire, Solène, primary, Lamore, Kristopher, additional, Laurence, Valérie, additional, Silva Moura, Daniela, additional, Marec-Berard, Perrine, additional, Leprince, Tanguy, additional, Corradini, Nadège, additional, Blin, Nicolas, additional, Chauvet, Sophie, additional, Seigneur, Etienne, additional, and Flahault, Cécile, additional

Published
2020
Full Text
View/download PDF

44. Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma

Author

Lin, Shu-Hong, primary, Sampson, Joshua N., additional, Grünewald, Thomas G. P., additional, Surdez, Didier, additional, Reynaud, Stephanie, additional, Mirabeau, Olivier, additional, Karlins, Eric, additional, Rubio, Rebeca Alba, additional, Zaidi, Sakina, additional, Grossetête-Lalami, Sandrine, additional, Ballet, Stelly, additional, Lapouble, Eve, additional, Laurence, Valérie, additional, Michon, Jean, additional, Pierron, Gaelle, additional, Kovar, Heinrich, additional, Kontny, Udo, additional, González-Neira, Anna, additional, Alonso, Javier, additional, Patino-Garcia, Ana, additional, Corradini, Nadège, additional, Bérard, Perrine Marec, additional, Miller, Jeremy, additional, Freedman, Neal D., additional, Rothman, Nathaniel, additional, Carter, Brian D., additional, Dagnall, Casey L., additional, Burdett, Laurie, additional, Jones, Kristine, additional, Manning, Michelle, additional, Wyatt, Kathleen, additional, Zhou, Weiyin, additional, Yeager, Meredith, additional, Cox, David G., additional, Hoover, Robert N., additional, Khan, Javed, additional, Armstrong, Gregory T., additional, Leisenring, Wendy M., additional, Bhatia, Smita, additional, Robison, Leslie L., additional, Kulozik, Andreas E., additional, Kriebel, Jennifer, additional, Meitinger, Thomas, additional, Metzler, Markus, additional, Krumbholz, Manuela, additional, Hartmann, Wolfgang, additional, Strauch, Konstantin, additional, Kirchner, Thomas, additional, Dirksen, Uta, additional, Mirabello, Lisa, additional, Tucker, Margaret A., additional, Tirode, Franck, additional, Morton, Lindsay M., additional, Chanock, Stephen J., additional, Delattre, Olivier, additional, and Machiela, Mitchell J., additional

Published
2020
Full Text
View/download PDF

45. Methotrexate–Etoposide–Ifosfamide Compared with Doxorubicin–Cisplatin–Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18–25 Years

Author

Marec-Berard, Perrine, primary, Laurence, Valérie, additional, Occean, Bob-Valéry, additional, Ray-Coquard, Isabelle, additional, Linassier, Claude, additional, Corradini, Nadège, additional, Collard, Olivier, additional, Chaigneau, Loïc, additional, Cupissol, Didier, additional, Kerbrat, Pierre, additional, Saada-Bouzid, Esma, additional, Delcambre, Corinne, additional, Gouin, François, additional, Guillemet, Cécile, additional, Jimenez, Marta, additional, Lervat, Cyril, additional, Gaspar, Nathalie, additional, Le Deley, Marie-Cécile, additional, Brugieres, Laurence, additional, and Piperno-Neumann, Sophie, additional

Published
2020
Full Text
View/download PDF

46. Extra-Renal Non-Cerebral Rhabdoid Tumours

Author

Bourdeaut, Franck, Fréneaux, Paul, Thuille, Bénédicte, Bergeron, Christophe, Laurence, Valérie, Brugières, Laurence, Vérité, Cécile, Michon, Jean, Delattre, Olivier, and Orbach, Daniel

Published
2008
Full Text
View/download PDF

47. Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study

Author

Piperno-Neumann, Sophie, Ray-Coquard, Isabelle, Occean, Bob-Valéry, Laurence, Valérie, Cupissol, Didier, Perrin, Christophe, Penel, Nicolas, Bompas, Emmanuelle, Rios, Maria, Le Cesne, Axel, Italiano, Antoine, Anract, Philippe, De Pinieux, Gonzague, Collard, Olivier, Bertucci, François, Duffaud, Florence, Le Deley, Marie-Cécile, Delaye, Jessy, Brugières, Laurence, Blay, Jean-Yves, Piperno‐Neumann, Sophie, Ray‐Coquard, Isabelle, Occean, Bob‐Valéry, Pinieux, Gonzague, Le Deley, Marie‐Cécile, Blay, Jean‐Yves, Institut Curie [Paris], Centre Léon Bérard [Lyon], Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Département d'Oncologie Médicale [Institut Curie, Paris], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Institut Bergonié [Bordeaux], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Service d’Oncologie Médicale [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), UNICANCER [Paris], Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], Service d'Oncologie Médicale, Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lille-UNICANCER, and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, Cancer Research, MESH: Osteosarcoma, [SDV]Life Sciences [q-bio], adult patients, Kaplan-Meier Estimate, Zoledronic Acid, Gastroenterology, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Etoposide, MESH: Etoposide, MESH: Aged, MESH: Middle Aged, MESH: Follow-Up Studies, Middle Aged, Prognosis, MESH: Bone Neoplasms, Neoadjuvant Therapy, 3. Good health, Survival Rate, MESH: Antineoplastic Combined Chemotherapy Protocols, MESH: Methotrexate, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Toxicity, Osteosarcoma, Female, France, Primary tumour size, medicine.drug, Adult, medicine.medical_specialty, Adolescent, MESH: Survival Rate, MESH: Neoadjuvant Therapy, Bone Neoplasms, Subgroup analysis, doxorubicin-cisplatin-ifosfamide regimen, MESH: Zoledronic Acid, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, MESH: Drug Administration Schedule, Disease-Free Survival, Drug Administration Schedule, MESH: Prognosis, Young Adult, 03 medical and health sciences, MESH: Doxorubicin, Internal medicine, osteosarcoma, medicine, Humans, Ifosfamide, MESH: Ifosfamide, MESH: Kaplan-Meier Estimate, Aged, MESH: Adolescent, MESH: Humans, Adult patients, business.industry, MESH: Adult, medicine.disease, Acute toxicity, MESH: Male, MESH: France, Regimen, Methotrexate, MESH: Cisplatin, Doxorubicin, MESH: Disease-Free Survival, Feasibility Studies, Cisplatin, business, MESH: Feasibility Studies, MESH: Female, Follow-Up Studies
Abstract

International audience; In the OS2006 study, patients younger than 18 years were treated with a methotrexate-based regimen (MTX), patients older than 25 years with a doxorubicin-cisplatin-ifosfamide-based regimen (API-AI), whereas patients aged 18-25 years received either API-AI or MTX. We herein report the prespecified subgroup analysis of the outcome of 106 patients treated with API-AI. Preoperative chemotherapy combined three doxorubicin-ifosfamide-cisplatin (API) and two doxorubicin-ifosfamide (AI) courses. Postoperative chemotherapy was assigned by risk group: localised patients with a good histological response (25 years. The primary tumours were axial in 28 patients (26%), and 28 (26%) presented with metastases. Ninety-six patients (91%) had surgery, conservative in 82 (85%); 36 patients (38%, 95% CI 28-48%) were good responders. Toxicity was manageable, with no significant difference in severe acute toxicity between patients aged >25 years and those younger. With a median follow-up of 4.8 years, the 5-year event-free survival and overall survival rates were 46% (95% CI 36-56) and 57% (95% CI 47-67), respectively. The primary tumour size and initial metastases correlated with a higher risk of event. In these 106 osteosarcoma adult patients, API-AI proved feasible with no excess of toxicity, and favourable activity despite poor-prognosis factors.

Published
2019

48. Liste des auteurs

Author

Gerardin Priscille, Boudailliez Bernard, Duverger Philippe, Apter Gisèle, Auvin Stéphane, Baubet Thierry, Belloncle Vincent, Benjelloun Mohamed Amine, Benarous Xavier, Blanchet-Collet Corinne, Bon-Saint-Côme Marie, Botbol Michel, Bouhours-Nouet Natacha, Bourges-Petit Élisabeth, Brechon Geneviève, Brival Marie-Laure, de Broca Sophie, Bronsard Guillaume, Brunelle Julie, Caflisch Marianne, Cailliez Apolline, Catheline Nicole, Caurier Bernard, Chambry Jean, Chobeaux François, Choquet Marie, Cochat Pierre, Cohen David, Cosseron Florent, Coutant Régis, Dayan Jacques, Desombre Hugues, Devernay-Lefort Marie, Falissard Bruno, Fillatre Marc, Fuseau Alain, Gamet Marie-Laure, Geron François, Gicquel Ludovic, Godart Nathalie, Godeau Emmanuelle, Goguel d'Allondans Thierry, Guedj Bourdiau Marie-Jeanne, Guile Jean-Marc, Guillery-Girard Bérengère, Guitton Corinne, Gutton Philippe, Harf Aurélie, Hefez Serge, Huerre Patrice, Jacquin Paul, Jeammet Philippe, Krebs Marie-Odile, Lachance Jocelyn, Lamour Patrick, Lasfar Malika, Laurence Valérie, Laurent-Levinson Claudine, Le Breton David, De Leersnyder Hélène, Lefevre Hervé, Lenoir Pascal, Mahé Emmanuel, Malka Jean, Marcelli Daniel, Marguet Christophe, Mary Pierre, Massabie Elsa, Mille Christian, Mirkovic Bojan, Minassian Sevan, Monegat Marlène, Moro Marie Rose, Mouterde Olivier, Pacoricona Alfaro Dibia Liz, Patton George, Phan Olivier, Picherot Georges, Piot Marie-Aude, Podlipski Marc-Antoine, Pommereau Xavier, Prétagut Stéphane, Purper-Ouakil Diane, Racle Laurence, Revah-Lévy Anne, Rey-Salmon Caroline, Riquin Élise, Rochet Thierry, Rouget Sébastien, Rufo Marcel, Sawyer Susan, Schroder Carmen, Sibeoni Jordan, Speranza Mario, Stheneur Chantal, Stora Michael, Teboul Roger, Tordjman Sylvie, de Tournemire Renaud, Tubiana-Rufi Nadia, Van Bogaert Patrick, Viaux-Savelon Sylvie, Votadoro Pablo, and Yavuz-Kodat Enise

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results